ArticleeLife2021
Endomembrane targeting of human OAS1 p46 augments antiviral activity.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
8.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Identifying factors contributing to increased susceptibility to COVID-19 risk: a systematic review of Mendelian randomization studies.International journal of epidemiology · 2022Pooled it
- Mitochondrial Abundant Heat Soluble (MAHS) Protein Expression Modulates Metabolic Dynamics in Human Adipose-Derived Stem Cells.International journal of molecular sciences · 2026Article
- SARS-CoV-2 5'-UTR stem-loops activate the antiviral protein oligoadenylate synthetase 1 (OAS1).The Journal of biological chemistry · 2026Article
- Alternative splicing broadens antiviral diversity at the human OAS2 locus.The EMBO journal · 2026Article
- Differential assembly of RNP granules via activation of distinct dsRNA sensors by adenovirus mutants.PLoS pathogens · 2026Article
- Article
- SARS-CoV-2 5'-UTR stem-loops activate the antiviral protein oligoadenylate synthetase 1 (OAS1).bioRxiv : the preprint server for biology · 2026Article
- RNA-binding proteins and ribonucleoproteins as determinants of immunity.Nature reviews. Immunology · 2026Review
- Article
- Unbiased cleavage site prediction uncovers viral antagonism of host innate immunity by SARS-CoV-2 3C-like protease.JCI insight · 2026Article
- Differential assembly of RNP granules via activation of distinct dsRNA sensors by adenovirus mutants.bioRxiv : the preprint server for biology · 2026Article
- IFITM3 deficiency drives SARS-CoV-2 adaptation while preserving variant-specific traits.Nature communications · 2026Article
- The OAS-RNase L pathway: Insights from experiments of nature.Science immunology · 2026Review
- Molecular arms races at the virus-host splicing interface and their pathogenic implications.Frontiers in microbiology · 2026Review
- The shared biomarkers and molecular mechanisms of systemic lupus erythematosus and type 2 diabetes.PloS one · 2026Article
- Innate immune activation and mitochondrial ROS induce acute and persistent cardiac conduction system dysfunction after COVID-19.JCI insight · 2025Article
- Article
- Review
- Lithium-induced neuroprotection in bipolar disorder: Translational insights into cytoskeletal and proteomic mechanisms.IBRO neuroscience reports · 2025Review
- Integrating whole genome and transcriptome sequencing to characterize the genetic architecture of isoform variation.Nature communications · 2025Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 9 institutions in 3 countries.
Frank W Soveg *Department of Immunology, School of Medicine, University of Washington, Seattle, United States.ORCID 0000-0002-3403-0190
Johannes Schwerk *Department of Immunology, School of Medicine, University of Washington, Seattle, United States.ORCID 0000-0002-5964-7162
Nandan S GokhaleDepartment of Immunology, School of Medicine, University of Washington, Seattle, United States.
Karen CerosalettiBenaroya Research Institute at Virginia Mason, Seattle, United States.ORCID 0000-0002-7403-6239
Julian R SmithDepartment of Immunology, School of Medicine, University of Washington, Seattle, United States.
Erola Pairo-CastineiraRoslin Institute, University of Edinburgh, Edinburgh, United Kingdom.
Alison M KellDepartment of Immunology, School of Medicine, University of Washington, Seattle, United States.
Adriana ForeroDepartment of Immunology, School of Medicine, University of Washington, Seattle, United States.ORCID 0000-0002-2698-658X
Shivam A ZaverDepartment of Microbiology, School of Medicine, University of Washington, Seattle, United States.
Katharina Esser-NobisDepartment of Immunology, School of Medicine, University of Washington, Seattle, United States.ORCID 0000-0002-9027-0391
Justin A RobyDepartment of Immunology, School of Medicine, University of Washington, Seattle, United States.
Tien-Ying HsiangDepartment of Immunology, School of Medicine, University of Washington, Seattle, United States.
Snehal OzarkarDepartment of Immunology, School of Medicine, University of Washington, Seattle, United States.
Jonathan M ClinganDepartment of Immunology, School of Medicine, University of Washington, Seattle, United States.ORCID 0000-0003-4729-0247
Eileen T McAnarneyDepartment of Microbiology and Immunology, University of Texas Medical Center, Galveston, United States.ORCID 0000-0003-2337-2889
Amy El StoneDepartment of Immunology, School of Medicine, University of Washington, Seattle, United States.ORCID 0000-0002-9140-6510
Uma MalhotraDepartment of Infectious Disease, Virginia Mason Medical Center, Seattle, United States.
Cate SpeakeBenaroya Research Institute at Virginia Mason, Seattle, United States.ORCID 0000-0003-1480-4272
Joseph PerezCancer Virology Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, United States.
Chiraag BaluDepartment of Immunology, School of Medicine, University of Washington, Seattle, United States.
Eric J AllenspachCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, United States.ORCID 0000-0001-7346-5835
Jennifer L HydeDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, United States.ORCID 0000-0001-8062-1672
Vineet D MenacheryDepartment of Microbiology and Immunology, University of Texas Medical Center, Galveston, United States.
Saumendra N SarkarCancer Virology Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, United States.ORCID 0000-0002-2850-6121
Joshua J WoodwardCenter for Innate Immunity and Immune Disease, University of Washington, Seattle, United States.ORCID 0000-0002-4630-403X
Daniel B StetsonDepartment of Immunology, School of Medicine, University of Washington, Seattle, United States.ORCID 0000-0002-5936-1113
John Kenneth BaillieRoslin Institute, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0001-5258-793X
Jane H BucknerBenaroya Research Institute at Virginia Mason, Seattle, United States.
Michael GaleDepartment of Immunology, School of Medicine, University of Washington, Seattle, United States.
Ram SavanDepartment of Immunology, School of Medicine, University of Washington, Seattle, United States.ORCID 0000-0002-3087-1355
University of Washington · USBenaroya Research InstituteRoslin Institute · GBTexas Medical Center · USUPMC Hillman Cancer Center · USCharles Sturt University · AUThe Ohio State University · USUniversity of New Mexico · USVirginia Mason Medical Center · US
Funding
Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8MUnlocking Zika Virus Immune Control and Pathogenesis with the Collaborative CrossU19AI100625 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MCWEENEY, SHANNON K. · 2012 to 2021
$36.6MTRAINING IN MOLECULAR AND CELLULAR BIOLOGYT32GM007270 · NIGMS · UNIVERSITY OF WASHINGTON · PI RAIBLE, DAVID W · 1985 to 2020
$21.0MEXPERIMENTAL PATHOLOGY OF CARDIOVASCULAR DISEASET32HL007312 · NHLBI · UNIVERSITY OF WASHINGTON · PI MAJESKY, MARK W., SCHWARTZ, STEPHEN MARK · 1985 to 2019
$11.8MIntracellular nucleic acid detection in autoimmunityR01AI084914 · NIAID · UNIVERSITY OF WASHINGTON · PI STETSON, DANIEL B · 2010 to 2024
$7.2MDiseases of Public Health Importance Training GrantT32AI007509 · NIAID · UNIVERSITY OF WASHINGTON · PI LUND, JENNIFER M · 1997 to 2024
$6.3MInnate Immune Regulation of Zika Virus InfectionR01AI145296 · NIAID · UNIVERSITY OF WASHINGTON · PI COYNE, CAROLYN B, DIAMOND, MICHAEL S · 2019 to 2023
$4.1MInnate Immune Control of West Nile VirusR01AI104002 · NIAID · UNIVERSITY OF WASHINGTON · PI DIAMOND, MICHAEL S, GALE, MICHAEL · 2013 to 2017
$3.7MMechanisms of hepatic innate immune activation by HCVR01AI127463 · NIAID · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL, ROSEN, HUGO RAMON · 2017 to 2021
$2.8MA new mechanism of antiviral activity of 2’-5’ Oligoadenylate Synthetase 1R01AI150214 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DIAMOND, MICHAEL S, SARKAR, SAUMENDRA N · 2020 to 2024
$2.6MThe Host Response to Hepatitis C VirusR01AI118916 · NIAID · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL · 2016 to 2020
$2.5MNovel regulatory mechanisms control IFNL3 expression during HCV infectionR01AI108765 · NIAID · UNIVERSITY OF WASHINGTON · PI SAVAN, RAM · 2014 to 2018
$2.3MMedical Research Council MC_PC_20004NHLBI NIH HHS T32 HL007312NIAID NIH HHS F31 AI140530NIAID NIH HHS R01 AI084914NIAID NIH HHS R01 AI104002NIAID NIH HHS R01 AI108765NIAID NIH HHS R01 AI118916NIAID NIH HHS R01 AI127463NIAID NIH HHS R01 AI145296NIAID NIH HHS R01 AI150214NIAID NIH HHS R21 AI135437NIAID NIH HHS R56 AI145974NIAID NIH HHS T32 AI007509NIAID NIH HHS T32 AI106677NIAID NIH HHS U19 AI100625NIGMS NIH HHS T32 GM007270NIH HHS AI100625NIH HHS AI104002NIH HHS AI104002,AI118916,AI145296,AI127463,AI100625NIH HHS AI106677NIH HHS AI106677,GM007270,AI140530NIH HHS AI108765NIH HHS AI118916NIH HHS AI127463NIH HHS AI135437NIH HHS AI140530NIH HHS AI145296NIH HHS AI145974NIH HHS AI145974,AI108765,AI135437NIH HHS GM007270NIH HHS P51 OD010425NIH HHS S10 OD026741NIH HHS T32 HL007312
Abstract
Many host RNA sensors are positioned in the cytosol to detect viral RNA during infection. However, most positive-strand RNA viruses replicate within a modified organelle co-opted from intracellular membranes of the endomembrane system, which shields viral products from cellular innate immune sensors. Targeting innate RNA sensors to the endomembrane system may enhance their ability to sense RNA generated by viruses that use these compartments for replication. Here, we reveal that an isoform of oligoadenylate synthetase 1, OAS1 p46, is prenylated and targeted to the endomembrane system. Membrane localization of OAS1 p46 confers enhanced access to viral replication sites and results in increased antiviral activity against a subset of RNA viruses including flaviviruses, picornaviruses, and SARS-CoV-2. Finally, our human genetic analysis shows that the
Indexed as
2',5'-Oligoadenylate SynthetaseAnimalsCell LineCOVID-19CRISPR-Cas SystemsGene EditingHumansPolymorphism, Single NucleotideSARS-CoV-22',5'-Oligoadenylate SynthetaseOAS1 protein, humanCOVID-19humanimmunologyinflammationinnate immunityinterferon stimulated genesRNA virusSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.